Observational GIMEMA Study on the Outcome of Acute Myeloid Leukemia (AML) Patients Treated With New Drugs in Real-life
This multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult AML patients.
• Aged 18 years or older
• AML diagnosis according to the ELN guidelines, excluding M3
• Signed Informed consent, if applicable
• Treatment initiation with novel drugs in monotherapy or combination, in accordance with the AIFA authorizations, from the AIFA registration up to 31.12.2027 with particular attention to:
‣ patients affected by FLT3-mutated AML treated with gilteritinib.
⁃ patients affected by IDH-mutated AML treated with IDH inhibitors.
⁃ patients affected by AML in maintenance therapy with oral azacytidine.
⁃ patients affected by AML treated with glasdegib.
⁃ patients affected by AML treated with gemtuzumab ozogamicin.
⁃ other novel drugs or combination for the treatment of AML approved during the study period.